Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
| Status: | Recruiting |
|---|---|
| Conditions: | Endocrine, Nephrology |
| Therapuetic Areas: | Endocrinology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | September 2014 |
| End Date: | September 2016 |
| Contact: | Sanjeev Akkina, MD |
| Email: | sakkina@uic.edu |
| Phone: | 312-996-8075 |
The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria
associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
Inclusion Criteria:
- Kidney transplant recipients with confirmed transplant glomerulopathy on kidney
biopsy.
- Failed standard therapy (>25% reduction in proteinuria) including maximum use of an
ACE inhibitor, ARB, or aldosterone blocker with a goal blood pressure less than
130/80 and optimization of their immunosuppression
Exclusion Criteria:
- Diabetes
We found this trial at
1
site
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
